{"id":"NCT01903265","sponsor":"Tonix Pharmaceuticals, Inc.","briefTitle":"BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)","officialTitle":"A Phase 2b, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Tablets Taken at Bedtime in Patients With Fibromyalgia","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2013-09","primaryCompletion":"2014-07","completion":"2014-09","firstPosted":"2013-07-19","resultsPosted":"2016-12-23","lastUpdate":"2016-12-23"},"enrollment":205,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Primary Fibromyalgia"],"interventions":[{"type":"DRUG","name":"TNX-102 SL 2.8mg","otherNames":["Low dose cyclobenzaprine sublingual tablets"]},{"type":"DRUG","name":"Placebo","otherNames":["Placebo sublingual tablets"]}],"arms":[{"label":"TNX-102 SL 2.8 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"TNX-102 capsules \\[formerly known as very low dose (VLD) cyclobenzaprine\\] at bedtime have shown promise as a treatment of fibromyalgia, but the drug required new formulation technology for bedtime use. The present trial was designed to assess the safety and efficacy of TNX-102 SL 2.8 mg tablets, taken daily at bedtime over 12 weeks to treat fibromyalgia.","primaryOutcome":{"measure":"Mean Change From Baseline in Weekly Average of Daily Pain Scores at Week 12","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"TNX-102 SL 2.8 mg Tablets","deltaMin":-1.39,"sd":0.253},{"arm":"Placebo","deltaMin":-0.95,"sd":0.271}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":8},"locations":{"siteCount":17,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":103},"commonTop":["hypoaesthesia oral","Somnolence","Back pain","Product taste abnormal","Nausea"]}}